Victory Capital Management Inc. Sells 3,292 Shares of Artivion, Inc. (NYSE:AORT)

Victory Capital Management Inc. trimmed its position in Artivion, Inc. (NYSE:AORT) by 2.9% in the 2nd quarter, Holdings Channel reports. The firm owned 112,179 shares of the company’s stock after selling 3,292 shares during the quarter. Victory Capital Management Inc.’s holdings in Artivion were worth $2,877,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its stake in Artivion by 2.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 326,085 shares of the company’s stock valued at $5,830,000 after buying an additional 8,090 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Artivion by 5.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,686,502 shares of the company’s stock valued at $30,156,000 after acquiring an additional 80,214 shares during the last quarter. Wasatch Advisors LP grew its holdings in shares of Artivion by 0.4% during the fourth quarter. Wasatch Advisors LP now owns 519,019 shares of the company’s stock worth $9,280,000 after purchasing an additional 2,287 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Artivion by 38.6% in the first quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock worth $38,000 after purchasing an additional 505 shares during the last quarter. Finally, Register Financial Advisors LLC purchased a new stake in Artivion in the first quarter valued at approximately $114,000. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Artivion

In related news, VP Matthew A. Getz sold 9,420 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $25.31, for a total transaction of $238,420.20. Following the completion of the sale, the vice president now directly owns 34,116 shares in the company, valued at approximately $863,475.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, VP Matthew A. Getz sold 9,420 shares of the company’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $25.31, for a total transaction of $238,420.20. Following the completion of the sale, the vice president now directly owns 34,116 shares in the company, valued at approximately $863,475.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Anthony B. Semedo sold 9,709 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $24.99, for a total transaction of $242,627.91. Following the completion of the sale, the director now directly owns 34,159 shares in the company, valued at approximately $853,633.41. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,679 shares of company stock worth $626,518. Company insiders own 8.10% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Needham & Company LLC reissued a “buy” rating and issued a $30.00 price target on shares of Artivion in a research note on Friday, August 9th. Lake Street Capital upped their target price on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, July 2nd. Stifel Nicolaus increased their target price on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, September 13th. Finally, Oppenheimer lifted their price target on Artivion from $25.00 to $30.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th.

Artivion Trading Down 0.6 %

AORT stock opened at $25.23 on Wednesday. The company has a market capitalization of $1.05 billion, a PE ratio of -105.13 and a beta of 1.74. The company has a debt-to-equity ratio of 1.07, a quick ratio of 4.04 and a current ratio of 5.63. Artivion, Inc. has a one year low of $12.16 and a one year high of $29.24. The company’s 50 day moving average price is $26.12 and its two-hundred day moving average price is $23.58.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, August 8th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.04. The company had revenue of $98.02 million for the quarter, compared to analysts’ expectations of $97.70 million. Artivion had a negative net margin of 2.22% and a positive return on equity of 3.81%. As a group, analysts predict that Artivion, Inc. will post 0.2 earnings per share for the current fiscal year.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.